Behavioral barcoding in the cloud: embracing data-intensive digital phenotyping in neuropharmacology

Cardiovascular Research Center and Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.
Trends in Biotechnology (Impact Factor: 10.04). 05/2012; 30(8):421-5. DOI: 10.1016/j.tibtech.2012.05.001
Source: PubMed

ABSTRACT For decades, studying the behavioral effects of individual drugs and genetic mutations has been at the heart of efforts to understand and treat nervous system disorders. High-throughput technologies adapted from other disciplines (e.g., high-throughput chemical screening, genomics) are changing the scale of data acquisition in behavioral neuroscience. Massive behavioral datasets are beginning to emerge, particularly from zebrafish labs, where behavioral assays can be performed rapidly and reproducibly in 96-well, high-throughput format. Mining these datasets and making comparisons across different assays are major challenges for the field. Here, we review behavioral barcoding, a process by which complex behavioral assays are reduced to a string of numeric features, facilitating analysis and comparison within and across datasets.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Due to several inherent advantages, zebrafish are being utilized in increasingly sophisticated screens to assess the physiological effects of chemical compounds directly in living vertebrate organisms. Diverse screening platforms showcase these advantages. Morphological assays encompassing basic qualitative observations to automated imaging, manipulation, and data-processing systems provide whole organism to subcellular levels of detail. Behavioral screens extend chemical screening to the level of complex systems. In addition, zebrafish-based disease models provide a means of identifying new potential therapeutic strategies. Automated systems for handling/sorting, high-resolution imaging and quantitative data collection have significantly increased throughput in recent years. These advances will make it easier to capture multiple streams of information from a given sample and facilitate integration of zebrafish at the earliest stages of the drug-discovery process, providing potential solutions to current drug-development bottlenecks. Here we outline advances that have been made within the growing field of zebrafish chemical screening.
    Future medicinal chemistry 09/2012; 4(14):1811-22. DOI:10.4155/fmc.12.115 · 4.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Zebrafish (Danio rerio) are offering novel perspectives to investigate the nervous system as a genetically and molecularly tractable in-vivo model of complex vertebrate behavior. The balance of low cost, experimental agility and phenotypic complexity, unique to zebrafish, empowers researchers to study biochemical regulators of development, behavior and disease pathogenesis in ways previously unapproachable. Larval zebrafish assays have demonstrated the value of integrating behavioral tests with high-throughput quantification techniques by successfully identifying psychotropic compounds and predicting neurological targets based on large-scale analysis of variation in behavioral responses. Pre-clinical drug discovery and behavioral genetics stands to benefit greatly from high-throughput screening assays using adult zebrafish. However, a characterization and quantification technique of adult zebrafish behavioral phenotypes requires standardization before such assays can be realized. This dissertation provides characterization of adult zebrafish behavior following ethological and pharmacological experimental treatments in affective and social domains. Behavior is quantified manually, as well as using automated video-tracking software, and correlated with a physiological biomarker (i.e. whole-body cortisol) to verify phenotypic states. In addition, a novel method of neurophenotyping using three-dimensional swim trajectory reconstructions is presented to enable rapid identification of treatment specific movement patterns. Collectively, this research provides a foundation for future studies pursing high-throughput behavioral phenotyping in adult zebrafish, and their application to modeling complex human disorders.
    12/2012, Degree: Neuroscience, Supervisor: Allan Kalueff
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Quantitative systems pharmacology (QSP) is a recent addition to the modeling and simulation toolbox for drug discovery and development and is based upon mathematical modeling of biophysical realistic biological processes in the disease area of interest. The combination of preclinical neurophysiology information with clinical data on pathology, imaging and clinical scales makes it a real translational tool. We will discuss the specific characteristics of QSP and where it differs from PK/PD modeling, such as the ability to provide support in target validation, clinical candidate selection and multi-target MedChem projects. In clinical development the approach can provide additional and unique evaluation of the effect of comedications, genotypes and disease states (patient populations) even before the initiation of actual trials. A powerful property is the ability to perform failure analysis. By giving examples from the CNS R&D field in schizophrenia and Alzheimer's disease, we will illustrate how this approach can make a difference for CNS R&D projects.
    Journal of Pharmacokinetics and Biopharmaceutics 01/2013; DOI:10.1007/s10928-013-9297-1 · 1.46 Impact Factor